Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cells
Open Access
- 30 January 2025
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-16
Abstract
Extracellular vesicles (EVs) are taken up by most cells, however specific or preferential cell targeting remains a hurdle. This study aims to develop an EV that targets cells involved in inflammation, specifically those expressing intercellular adhesion molecule-1 (ICAM-1). To target these cells, we overexpress the ICAM-1 binding receptor “lymphocyte function-associated antigen-1” (LFA-1) in HEK293F cells, by sequential transfection of plasmids of the two LFA-1 subunits, ITGAL and ITGB2 (CD11a and CD18). The LFA-1 receptor was strongly overexpressed on the EVs released by the transfected cells. We further loaded these EVs with a therapeutic peptide, targeting myeloid differentiation primary response 88 (Myd88; EVMyd88), through a developed EV open-and-close procedure. Myd88 is a downstream common intracellular messenger for most TLR-receptors. EV expression of LFA-1 increases EV binding to ICAM-1-expressing cells, an effect that was dose-dependently inhibited by a specific neutralizing ICAM-1 antibody. Further, activated human endothelial cells treated with LFA-1 EVMyd88 had increased uptake of these EVs, resulting in dose-dependent inhibition of induced release of IL-8, presumably by targeting Myd88. We conclude that LFA-1-expressing EVMyd88 may be a candidate suitable for delivering therapeutic peptides in inflammatory diseases associated with TLR-activation. Graphical AbstractKeywords
Funding Information
- Hjärt-Lungfonden (244018078)
- Vetenskapsrådet (254018063)
- University of Gothenburg
This publication has 46 references indexed in Scilit:
- Engineered extracellular vesicles expressing ICAM-1: A promising targeted delivery system for T cell modificationsBiochimica et Biophysica Acta (BBA) - General Subjects, 2023
- Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseasesJournal of Extracellular Vesicles, 2023
- Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse modelsJournal of Extracellular Vesicles, 2022
- Engineered Cell‐Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple‐Negative Breast Cancer in MiceAdvanced Healthcare Materials, 2021
- Quantification of protein cargo loading into engineered extracellular vesicles at single‐vesicle and single‐molecule resolutionJournal of Extracellular Vesicles, 2021
- Engineered synthetic cell penetrating peptide with intracellular anti‐inflammatory bioactivity: An in vitro and in vivo studyJournal of Biomedical Materials Research Part A, 2021
- Engineered Extracellular Vesicles for Cancer TherapyAdvanced Materials, 2021
- The Challenges and Possibilities of Extracellular Vesicles as Therapeutic VehiclesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Inhibition of MyD88 Signaling Skews Microglia/Macrophage Polarization and Attenuates Neuronal Apoptosis in the Hippocampus After Status Epilepticus in MiceNeurotherapeutics, 2018
- Structural and mechanical functions of integrinsBiophysical Reviews, 2013